drugset
drugset / Trial / NCT01798303

A Study of LY2940094 in Participants With Alcohol Dependency

NCT01798303 ↗

Phase 2 Completed 88 enrolled BlackThorn Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.

Timeline

Start
2013-07
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2940094 Small molecule 40 mg Oral

Indications

alcohol dependence